[Ip-health] FDA approves first combination pill to treat hepatitis C

Peter Maybarduk pmaybarduk at citizen.org
Fri Oct 10 13:02:37 PDT 2014


From: U.S. Food & Drug Administration (FDA) [mailto:fda at service.govdelivery.com]
Sent: Friday, October 10, 2014 1:52 PM
Subject: Drug Information Update- FDA approves first combination pill to treat hepatitis C



The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.

________________________________

The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.

Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.

Both drugs in Harvoni interfere with the enzymes needed by HCV to multiply. Sofosbuvir is a previously approved HCV drug marketed under the brand name Sovaldi. Harvoni also contains a new drug called ledipasvir.

For more information, please visit: Harvoni<http://links.govdelivery.com:80/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTQxMDEwLjM2OTIxMzgxJm1lc3NhZ2VpZD1NREItUFJELUJVTC0yMDE0MTAxMC4zNjkyMTM4MSZkYXRhYmFzZWlkPTEwMDEmc2VyaWFsPTE2OTcwMjgwJmVtYWlsaWQ9bWNhcm9tZUBjaXRpemVuLm9yZyZ1c2VyaWQ9bWNhcm9tZUBjaXRpemVuLm9yZyZmbD0mZXh0cmE9TXVsdGl2YXJpYXRlSWQ9JiYm&&&100&&&http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery>.

________________________________

This is an automated message delivery system.  Replying to this message will not reach DDI staff.  If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm ET Monday - Friday.  You can also email us at druginfo at fda.hhs.gov<mailto:druginfo at fda.hhs.gov>.

  *   For additional drug information, please visit the DDI Web page<http://links.govdelivery.com:80/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTQxMDEwLjM2OTIxMzgxJm1lc3NhZ2VpZD1NREItUFJELUJVTC0yMDE0MTAxMC4zNjkyMTM4MSZkYXRhYmFzZWlkPTEwMDEmc2VyaWFsPTE2OTcwMjgwJmVtYWlsaWQ9bWNhcm9tZUBjaXRpemVuLm9yZyZ1c2VyaWQ9bWNhcm9tZUBjaXRpemVuLm9yZyZmbD0mZXh0cmE9TXVsdGl2YXJpYXRlSWQ9JiYm&&&101&&&http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm082585.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery>.
  *   For up-to-date drug information, follow the FDA's Division of Drug Information on Twitter: FDA_Drug_Info<http://links.govdelivery.com:80/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTQxMDEwLjM2OTIxMzgxJm1lc3NhZ2VpZD1NREItUFJELUJVTC0yMDE0MTAxMC4zNjkyMTM4MSZkYXRhYmFzZWlkPTEwMDEmc2VyaWFsPTE2OTcwMjgwJmVtYWlsaWQ9bWNhcm9tZUBjaXRpemVuLm9yZyZ1c2VyaWQ9bWNhcm9tZUBjaXRpemVuLm9yZyZmbD0mZXh0cmE9TXVsdGl2YXJpYXRlSWQ9JiYm&&&102&&&https://twitter.com/FDA_Drug_Info?source=govdelivery&utm_medium=email&utm_source=govdelivery>.
  *   This service is provided to you at no charge by the U.S. Food & Drug Administration (FDA)<http://links.govdelivery.com:80/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTQxMDEwLjM2OTIxMzgxJm1lc3NhZ2VpZD1NREItUFJELUJVTC0yMDE0MTAxMC4zNjkyMTM4MSZkYXRhYmFzZWlkPTEwMDEmc2VyaWFsPTE2OTcwMjgwJmVtYWlsaWQ9bWNhcm9tZUBjaXRpemVuLm9yZyZ1c2VyaWQ9bWNhcm9tZUBjaXRpemVuLm9yZyZmbD0mZXh0cmE9TXVsdGl2YXJpYXRlSWQ9JiYm&&&103&&&http://www.fda.gov/?source=govdelivery&utm_medium=email&utm_source=govdelivery>.

________________________________

[FDA Logo]<http://links.govdelivery.com:80/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTQxMDEwLjM2OTIxMzgxJm1lc3NhZ2VpZD1NREItUFJELUJVTC0yMDE0MTAxMC4zNjkyMTM4MSZkYXRhYmFzZWlkPTEwMDEmc2VyaWFsPTE2OTcwMjgwJmVtYWlsaWQ9bWNhcm9tZUBjaXRpemVuLm9yZyZ1c2VyaWQ9bWNhcm9tZUBjaXRpemVuLm9yZyZmbD0mZXh0cmE9TXVsdGl2YXJpYXRlSWQ9JiYm&&&104&&&http://www.fda.gov/?source=govdelivery&utm_medium=email&utm_source=govdelivery>



More information about the Ip-health mailing list